IMRX Profile
Immuneering Corporation is a biopharmaceutical firm dedicated to advancing product candidates in the fields of oncology and neuroscience. The company’s leading oncology assets include IMM-1-104, a dual-MEK inhibitor designed to target cancers associated with mutations in RAS and/or RAF, such as pancreatic, melanoma, colorectal, and non-small cell lung cancers. Another notable candidate, IMM-6-415, is focused on treating solid tumors, representing a key element of the company's oncology portfolio.
In addition to these lead programs, Immuneering is advancing five oncology programs in the discovery stage. These programs are aimed at targeting critical components of the MAPK or mTOR signaling pathways, which are pivotal in the development and progression of various cancers. The company's research in these areas reflects a commitment to identifying novel therapeutic approaches for challenging cancer types.
Immuneering is also actively pursuing two discovery-stage neuroscience programs, focusing on innovative treatments for neurological conditions. These programs are part of the company's broader strategy to leverage its expertise in drug development to address unmet needs in both oncology and neuroscience.
Established in 2008 and headquartered in Cambridge, Massachusetts, Immuneering Corporation was previously a subsidiary of Teva Pharmaceutical Industries Limited. The company’s strategic focus on cutting-edge research and development underscores its commitment to delivering transformative therapies and advancing scientific understanding in its targeted therapeutic areas.
|
